Figure 1. Immunohistochemistry for ER and PR positives, intensity +++ in 95% tumor cells (× 40 field). ER: estrogen receptor; PR: progesterone receptor.
| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website https://www.wjon.org |
Original Article
Volume 12, Number 4, August 2021, pages 119-123
Prevalence and Molecular Profile of Breast Carcinoma Using Immunohistochemistry Markers in Mexican Women
Figures
Tables
| Molecular subtype | All patients (n = 379) | Patients aged ≤ 40 years (n = 48) | Patients aged > 40 years (n = 331) | Carcinoma NST (n = 269) | Lobular carcinoma (n = 51) | Medullary carcinoma (n = 9) | Mucinous carcinoma (n = 5) |
|---|---|---|---|---|---|---|---|
| aLuminal A: ER or PR+, HER2-, and Ki-67 low (< 14%). bLuminal B: ER or PR+, HER2-/+, and Ki-67 (HER2- > 14%, HER2+ any %). cHER2-positive: ER-, PR-, HER2+ (at least > 10% of tumor cells complete membrane) and Ki-67 low/high. dTriple-negative/basal-like: ER-, PR-, HER2-, Ki-67 low/high. ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; PR: progesterone receptor; NST: no special type. | |||||||
| Luminal Aa | 139 (36.67%) | 7 (14.58%) | 132 (39.87%) | 81 (30%) | 27 (53%) | 0 (0%) | 5 (100%) |
| Luminal Bb | 143 (37.73%) | 26 (54.16%) | 117 (35.34%) | 110 (41%) | 17 (33%) | 0 (0%) | 0 (0%) |
| HER2-positivec | 32 (8.44%) | 3 (6.25%) | 29 (8.76%) | 31 (12%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Triple-negatived | 65 (17.15%) | 12 (25%) | 53 (16.01%) | 47 (17%) | 7 (14%) | 9 (100%) | 0 (0%) |
| Comorbidities | All patients (n = 379) | Patients aged ≤ 40 years (n = 48) | Patients aged > 40 years (n = 331) |
|---|---|---|---|
| Diabetes | 43 (11.34%) | 2 (4.16%) | 41 (12.38%) |
| Hypertension | 78 (20.58%) | 1 (2.08%) | 77 (23.26%) |
| Obesity | 82 (21.63%) | 1 (2.08%) | 81 (24.27%) |
| History of hormonal replacement/contraceptives | 66 (17.41%) | 5 (10.41%) | 61 (18.42%) |